TY - JOUR
T1 - The Collaborative Ocular Tuberculosis Study (COTS)-1
T2 - A Multinational Review of 165 Patients with Tubercular Anterior Uveitis
AU - Agrawal, Rupesh
AU - Betzler, Bjorn
AU - Testi, Ilaria
AU - Mahajan, Sarakshi
AU - Agarwal, Aniruddha
AU - Gunasekeran, Dinesh Visva
AU - Raje, Dhananjay
AU - Aggarwal, Kanika
AU - Murthy, Somasheila I.
AU - Westcott, Mark
AU - Chee, Soon Phaik
AU - Mccluskey, Peter
AU - Ho, Su Ling
AU - Teoh, Stephen
AU - Cimino, Luca
AU - Biswas, Jyotirmay
AU - Narain, Shishir
AU - Agarwal, Manisha
AU - Mahendradas, Padmamalini
AU - Khairallah, Moncef
AU - Jones, Nicholas
AU - Tugal-Tutkun, Ilknur
AU - Babu, Kalpana
AU - Basu, Soumayava
AU - Carreño, Ester
AU - Lee, Richard
AU - Al-Dhibi, Hassan
AU - Bodaghi, Bahram
AU - Invernizzi, Alessandro
AU - Goldstein, Debra A.
AU - Herbort, Carl P.
AU - Barisani-Asenbauer, Talin
AU - González-López, Julio J.
AU - Androudi, Sofia
AU - Bansal, Reema
AU - Moharana, Bruttendu
AU - Esposti, Simona
AU - Tasiopoulou, Anastasia
AU - Nadarajah, Sengal
AU - Agarwal, Mamta
AU - Abraham, Sharanya
AU - Vala, Ruchi
AU - Singh, Ramandeep
AU - Sharma, Aman
AU - Sharma, Kusum
AU - Zierhut, Manfred
AU - Kon, Onn Min
AU - Cunningham, Emmett T.
AU - Kempen, John H.
AU - Nguyen, Quan Dong
AU - Pavesio, Carlos
AU - Gupta, Vishali
N1 - Funding Information:
The research was partially funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. This sponsor supported some of the research man-hours that were contributed by all our part-time collaborators from the Moorfields Eye Hospital that are salaried as Ophthalmology clinicians by the hospital. Debra A. Goldstein is supported by an unrestricted grant from Research to Prevent Blindness (RPB). Vishali Gupta is supported by grant from Department of Biotechnology (DBT), India. Julio J GONZ?LEZ-L?PEZ2 is supported by study grants from Abbvie, Allergan, and Angelini. Funders played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication. Rupesh AGRAWAL, Dinesh Visva GUNASEKERAN, and Dhananjay RAJE had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Funding Information:
The authors report no conflicts of interest, financial or non-financial, in the subject matter or materials discussed in this manuscript. Prof Kempen is consultant for Gilead (DSMC chair) and also equity owner for Betaliq. The work was supported by NIHR biomedical research, UK. The authors alone are responsible for the content and writing of the paper.
Publisher Copyright:
© 2020, © 2020 Taylor & Francis Group, LLC.
PY - 2020
Y1 - 2020
N2 - Purpose: The Collaborative Ocular Tuberculosis Study (COTS) Group sought to address the diagnostic uncertainty through retrospective cohort analysis of treatment regimens and therapeutic outcomes for patients with tubercular Anterior Uveitis (TAU) across international centers. Methods: Multicentre retrospective analysis of patients diagnosed with TAU between January 2004 to December 2014 that had a minimum follow-up of 1 year. Results: One hundred and sixty-five patients were included. One hundred and seven subjects received antitubercular therapy (ATT) (n = 107/165; 64.9%) with all the patients receiving topical steroid therapy. Treatment failure was noted in 17 patients (n = 17/165; 10.3%), more frequently described in patients that received ATT (n = 13/107, 12.2%), than those that did not receive ATT (n = 4/58, 6.9%). Conclusion: In this retrospective study, addition of ATT did not have any statistically significant impact on outcome in patients with TAU.
AB - Purpose: The Collaborative Ocular Tuberculosis Study (COTS) Group sought to address the diagnostic uncertainty through retrospective cohort analysis of treatment regimens and therapeutic outcomes for patients with tubercular Anterior Uveitis (TAU) across international centers. Methods: Multicentre retrospective analysis of patients diagnosed with TAU between January 2004 to December 2014 that had a minimum follow-up of 1 year. Results: One hundred and sixty-five patients were included. One hundred and seven subjects received antitubercular therapy (ATT) (n = 107/165; 64.9%) with all the patients receiving topical steroid therapy. Treatment failure was noted in 17 patients (n = 17/165; 10.3%), more frequently described in patients that received ATT (n = 13/107, 12.2%), than those that did not receive ATT (n = 4/58, 6.9%). Conclusion: In this retrospective study, addition of ATT did not have any statistically significant impact on outcome in patients with TAU.
KW - Anti-tubercular therapy
KW - collaborative ocular tuberculosis study (COTS)
KW - ocular tuberculosis
KW - tubercular anterior uveitis
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85087505413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087505413&partnerID=8YFLogxK
U2 - 10.1080/09273948.2020.1761400
DO - 10.1080/09273948.2020.1761400
M3 - Article
C2 - 32600163
AN - SCOPUS:85087505413
SN - 0927-3948
SP - 1
EP - 10
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
ER -
